Page last updated: 2024-09-04

ezetimibe and Coronary Artery Stenosis

ezetimibe has been researched along with Coronary Artery Stenosis in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Ha, K; Han, SH; Jang, AY; Kang, WC; Kim, M; Lee, K; Moon, J; Oh, PC; Suh, SY	1
Hattori, E; Hirao, K; Kasano, K; Matsumoto, S; Nakamura, S; Teng, Y; Tokunaga, T; Yamamoto, T; Yonetsu, T; Yoshiwara, H	1
Coakley, J; Forbes, DA; Martin, AC; Sullivan, DR; Watts, GF	1

Trials

1 trial(s) available for ezetimibe and Coronary Artery Stenosis

Article	Year
Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. The American journal of cardiology, 2021, 09-01, Volume: 154 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Spectroscopy, Near-Infrared; Ultrasonography, Interventional	2021

Article

Year

Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis.

The American journal of cardiology, 2021, 09-01, Volume: 154

Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Spectroscopy, Near-Infrared; Ultrasonography, Interventional

2021

Other Studies

3 other study(ies) available for ezetimibe and Coronary Artery Stenosis

Article	Year
Impact of intensively lowered low-density lipoprotein cholesterol on deferred lesion prognosis. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2020, 03-01, Volume: 95, Issue:4 Topics: Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Time-to-Treatment; Treatment Outcome	2020
[Stable coronary heart disease--lessons from the COURAGE Study. With intensive drug therapy on the success track]. MMW Fortschritte der Medizin, 2008, Jun-05, Volume: 150, Issue:23 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Combined Modality Therapy; Coronary Disease; Coronary Stenosis; Death, Sudden, Cardiac; Ezetimibe; Humans; Kaplan-Meier Estimate; Life Style; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic; Simvastatin	2008
Familial hypercholesterolaemia in children and adolescents: a new paediatric model of care. Journal of paediatrics and child health, 2013, Volume: 49, Issue:4 Topics: Adolescent; Adult; Anticholesteremic Agents; Atherosclerosis; Azetidines; Child; Congenital Abnormalities; Coronary Stenosis; Disease Progression; Early Diagnosis; Ezetimibe; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Standard of Care	2013